Abstract
BackgroundIgE binding via the high affinity FceRI receptor modu-lates FceRI expression and cytokine production in mastcells. Antigen crosslinking of bound IgE further activatesmast cells, inducing degranulation and inflammatorymediator release. Omalizumab (Xolair; Genentech Inc)is a recombinant human monoclonal anti-IgE antibodythat prevents IgE binding to FceRI.ObjectiveWe investigated the effects of omalizumab on IgE-mediated responses in human mast cells.MethodsLAD2 and CD34
Highlights
IgE binding via the high affinity FcεRI receptor modulates FcεRI expression and cytokine production in mast cells
We investigated the effects of omalizumab on IgEmediated responses in human mast cells
This data suggests that omalizumab is an effective inhibitor of both sensitized and unsensitized human mast cells
Summary
IgE binding via the high affinity FcεRI receptor modulates FcεRI expression and cytokine production in mast cells. Antigen crosslinking of bound IgE further activates mast cells, inducing degranulation and inflammatory mediator release. Omalizumab (Xolair; Genentech Inc) is a recombinant human monoclonal anti-IgE antibody that prevents IgE binding to FcεRI
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
